ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

RegulatoryapprovedANKTIVAPositive

AI Analysis

Summary

ImmunityBio received marketing authorization from the United Arab Emirates for ANKTIVA to treat BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This represents a regulatory milestone in a non-major market.

Outcome Details

United Arab Emirates marketing authorization granted for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer for carcinoma in situ and papillary disease, and metastatic non-small cell lung cancer

Importance:5/10

Sentiment:

0.70

regulatory approvalinternational marketing authorizationbladder cancerlung cancerUAE

Related Companies

$IBRX

Read the original article

Published by yahoo_finance on July 29, 2026 10:45 PM

Read Original